Portal de Periódicos da CAPES

Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals

2019; Springer Science+Business Media; Volume: 16; Issue: 4 Linguagem: Inglês

10.1007/s11904-019-00450-9

1548-3576

Matthew R. Beymer, Ian W. Holloway, Craig Pulsipher, Raphael J. Landovitz,

Reproductive tract infections research

Pre-exposure prophylaxis (PrEP) is a potent HIV prevention strategy, but uptake of daily oral PrEP remains low. This review covers PrEP agents currently available and agents and modalities under investigation.Injectable ARV preparations have high acceptability among users but are likely to require adherence to 8-week interval injections. Topical microbicide gels and vaginal rings have underperformed by intention-to-treat analyses in efficacy studies, at least in large part due to challenges with adherence and/or sustained use. However, daily oral TDF-FTC also underperformed in randomized, placebo-controlled trials compared to expectations and subsequent real-world pragmatic use. On-demand (2-1-1 dosing strategy for MSM) and injectable PrEP appear to be acceptable among participants in clinical trials. These modalities are particularly compelling alternatives for individuals who either do not want to take a daily medication (both on-demand and injectable) and/or want to take PrEP without a long commitment (on-demand). Emerging modalities such as vaginal films, microneedles, and subdermal implants have numerous advantages but are still in early stages of development.